某院2024年"双通道"外配处方用药合理性分析OA

Objective To provide data reference for relevant management departments to carry out refined management of the entire process of"dual-channel"out-of-hospital prescription drugs.Methods A total of 58 043 outpatient"dual channel"out-of-hospital prescriptions from a tertiary comprehensive hospital in Chongqing for the whole year of 2024 were collected through the hospital information system(HIS),and the commonly used departments and drugs for those prescriptions were analyzed.A total of 2 551 065 prescription review data for 2024 from the hospital's rational drug use software was extracted,and the hospital's rational drug use management system and pharmacist manual review were adopted to evaluate all prescriptions and assess their rationality.Results The top three departments in terms of out-of-hospital prescription volume were Hematology(8 851 prescriptions,15.25%),Nephrology(7 990 prescriptions,13.77%),and Endocrinology(7 071 prescriptions,12.18%);the top three drugs were Finerenone Tablets(5 718 tablets,9.85%),Desvenlafaxine Succinate Sustained-release Tablets(5 136 tablets,8.85%),and Denosumab Injection(3 456 tablets,5.95%),which belonged to endocrine system or nervous system drugs.A total of 659 irrational prescriptions(700 items)were found in the out-of-hospital prescription review,with a rationality rate of 98.86%,which was lower than the 99.98%rationality rate for prescriptions in the hospital's supply catalog.The number of irrational out-of-hospital prescriptions were ranked as follows:inappropriate route of administration(376 prescriptions,57.06%),inappropriate usage and dosage(237 prescriptions,35.96%),drug interactions(46 prescriptions,6.98%),and inappropriate indications(41 prescriptions,6.22%),and there were differences in the composition of irrational prescriptions compared to those in the hospital.Conclusion The rationality rate of"dual-channel"out-of-hospital prescription is relatively high and meets national standards,but there is still room for improvement.Meanwhile,the higher prescription rationality rate also enhances the feasibility of implementing the"dual-channel"policy,further improving the accessibility of drugs negotiated by the country and benefiting more patients.